Russian academics exhibited a novel apparatus able to detect early phases of colon, lung, and pancreatic cancer within minutes. The assessment is conducted using a saliva sample and avoids invasive procedures.
Specialists from MIPT, the Russian Academy of Sciences’ Institute of General Physics, MIET, and Sirius University labored on the advancement. The primary goal was mastering the detection of ailment traces in bodily fluids where marker concentration is extremely low. The developed biosensor features superior sensitivity and recognizes even isolated molecules of hazardous proteins.
The foundation of the apparatus is a DNA segment fixed onto a graphene base. It reacts solely to proteins connected with tumor progression, disregarding extraneous substances. The device operates in dual modes, which lessens the chance of errors and yields accuracy comparable to clinical laboratory tests.
The creators of this innovation shared a desire to render health checks accessible to everyone. Regarding cost and ease of operation, the test resembles using a glucometer, enabling rapid screening both in medical facilities and at residence. This enhances the prospects of timely disease identification.
Beyond initial diagnosis, the instrument will be useful for monitoring therapy: it aids in tracking levels of tumor markers subsequent to surgery or a course of treatment. Should readings begin to escalate, physicians can more swiftly notice a potential recurrence of the illness and adjust treatment accordingly.
About the Author
